Clene Inc. agreed to sell 1,219,513 common shares at $3.28 each, targeting approximately $4.0 million in gross proceeds. Investors should note that the planned funds are earmarked for regulatory dialogue, filings and a new drug application for CNM-Au8, as well as expanded access, potential commercialization and Manufacturing expansion.

Key Highlights

  • The offering is expected to generate approximately $4.0 million in gross proceeds.
  • Existing stockholders, including certain Clene directors and officers, are among the purchasers.
  • Certain existing stockholders are purchasing the shares.

Clene Inc. (NASDAQ: CLNN) agreed to issue and sell 1,219,513 shares of common stock at $3.28 per share, with gross proceeds expected to reach approximately $4.0 million. The planned Capital would support regulatory dialogue and preparation of filings for lead drug candidate CNM-Au8, while also funding potential commercialization and manufacturing expansion.

$4.0M Offering Tied to CNM-Au8 Plans

The securities purchase agreement is dated September 15, 2026, and covers Clene Inc. common stock with a Par Value of $0.0001 per share. Existing stockholders, including certain directors and officers, signed as purchasers under the agreement. The closing was expected on September 17, 2026. Clene plans to combine the net proceeds with existing cash for general corporate purposes, primarily expenses connected with continued regulatory dialogue, regulatory filing preparation and a new drug application for CNM-Au8. The agreement contains customary representations, warranties, covenants, closing conditions, indemnification obligations to purchasers, other party obligations and termination provisions.